Novavax stock surges 15.56% and outperforms competitors

10 articles · Updated · MarketWatch · May 6

Shares closed at $9.36 on Wednesday, marking a second straight gain as trading volume jumped to 16.5 million from a 50-day average of 4.2 million.
The stock remained 21.8% below its 52-week high of $11.97 reached on 26 February, despite beating peers including Johnson & Johnson, Pfizer and Merck.
The move came during a broad market rally, with the Nasdaq Composite rising 2.02% and the Dow Jones Industrial Average gaining 1.24%.

Novavax's stock surged on a new strategy, but can it overcome activist pressure and high short interest for long-term success?

With major pharma licensing its adjuvant, is Novavax building a new revenue empire or just selling its crown jewels?